share_log

Aditxt | S-3/A: Registration statement for specified transactions by certain issuers (Amendment)

Aditxt | S-3/A: Registration statement for specified transactions by certain issuers (Amendment)

Aditxt | S-3/A:特定交易註冊聲明(修正)
美股SEC公告 ·  09/12 05:21

牛牛AI助理已提取核心訊息

Aditxt, Inc., a biotech company based in Delaware, filed an Amendment No. 1 to Form S-3 on Form S-1 with the U.S. Securities and Exchange Commission (SEC) on September 11, 2024. This amendment converts a previously filed Registration Statement on Form S-3 into a Registration Statement on Form S-1. The company, headquartered in Mountain View, California, is led by CEO Amro Albanna. The prospectus summary indicates that Aditxt is offering up to $150,000,000 of common stock to Seven Knots, LLC under a common stock purchase agreement dated May 2, 2024. The company's common stock is listed on The Nasdaq Capital Market under the symbol 'ADTX.' As of September 10, 2024, the stock was priced at $0.496 per share. Aditxt's business model involves securing, growing, and monetizing...Show More
Aditxt, Inc., a biotech company based in Delaware, filed an Amendment No. 1 to Form S-3 on Form S-1 with the U.S. Securities and Exchange Commission (SEC) on September 11, 2024. This amendment converts a previously filed Registration Statement on Form S-3 into a Registration Statement on Form S-1. The company, headquartered in Mountain View, California, is led by CEO Amro Albanna. The prospectus summary indicates that Aditxt is offering up to $150,000,000 of common stock to Seven Knots, LLC under a common stock purchase agreement dated May 2, 2024. The company's common stock is listed on The Nasdaq Capital Market under the symbol 'ADTX.' As of September 10, 2024, the stock was priced at $0.496 per share. Aditxt's business model involves securing, growing, and monetizing health innovations, with a focus on immune health, precision health, population health, women's health, and neurologic health. The company has several programs in various stages of development and seeks to acquire complementary assets through strategic transactions. Aditxt has entered into several agreements, including clinical trial agreements with Mayo Clinic and licensing agreements with Stanford University and MDNA Life Sciences, Inc. The company has also formed subsidiaries such as Adimune and Pearsanta to advance its therapeutic and diagnostic technologies. Additionally, Aditxt has entered into an asset purchase agreement to acquire antiviral products and has agreements related to senior notes and an equity line of credit. The company has also filed an amendment to its Certificate of Incorporation to increase authorized common stock and has entered into an amended and restated merger agreement with Evofem Biosciences, Inc.
總部位於特拉華州的生物科技公司Aditxt, Inc.於2024年9月11日向美國證券交易委員會(SEC)提交了關於表格S-3的修正案1號和關於表格S-1的註冊聲明。該修正案將之前提交的關於表格S-3的註冊聲明轉換爲關於表格S-1的註冊聲明。該公司總部位於加利福尼亞州山景城,首席執行官爲Amro Albanna。招股書摘要顯示,Aditxt擬向Seven Knots, LLC提供高達1.5億美元的普通股,根據2024年5月2日簽署的一份普通股購買協議。該公司的普通股在納斯達克資本市場上以「ADTX」標的進行交易。截至2024年9月10日,該股票價格爲每股0.496美元。Aditxt的業務模式涉...展開全部
總部位於特拉華州的生物科技公司Aditxt, Inc.於2024年9月11日向美國證券交易委員會(SEC)提交了關於表格S-3的修正案1號和關於表格S-1的註冊聲明。該修正案將之前提交的關於表格S-3的註冊聲明轉換爲關於表格S-1的註冊聲明。該公司總部位於加利福尼亞州山景城,首席執行官爲Amro Albanna。招股書摘要顯示,Aditxt擬向Seven Knots, LLC提供高達1.5億美元的普通股,根據2024年5月2日簽署的一份普通股購買協議。該公司的普通股在納斯達克資本市場上以「ADTX」標的進行交易。截至2024年9月10日,該股票價格爲每股0.496美元。Aditxt的業務模式涉及保障、增長和獲取健康創新,並專注於免疫健康、精準健康、人群健康、婦女健康和神經健康。該公司在不同階段開發了多個項目,並尋求通過戰略交易收購相關資產。Aditxt已與Mayo Clinic簽署了多項臨床試驗協議,並與斯坦福大學和MDNA Life Sciences, Inc.簽署了許可協議。該公司還成立了Adimune和Pearsanta等子公司,以推進其治療和診斷技術。此外,Aditxt已簽署了一項資產購買協議,以收購抗病毒產品,並與高級票據和股權授信相關的協議。該公司還修訂了其公司章程,以增加授權的普通股,並已簽署了與Evofem Biosciences, Inc.的修訂並重述的合併協議。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。